Participants in this research study have been diagnosed with multiple myeloma or POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin changes, which is a syndrome in which patients have a plasma cell disease resembling multiple myeloma, and various organ changes).
The purpose of this research study is to find out whether relapse or disease progression will be delayed when an autologous stem cell transplant (a transplant using your own stem cells) is combined with consolidation and maintenance treatment after transplant, and how safely this treatment can be given in patients with myeloma who are 65 years of age or older.
All of the drugs that will be used are commercially available, are FDA approved for one or more cancers, and have been used in the treatment of multiple myeloma and/or other cancers. However, the drugs Doxorubicin, Etoposide, and Cisplatin are not FDA approved specifically for the treatment of multiple myeloma.
Approximately 41 people will take part in this study conducted by investigators at the University of Iowa. This study will only be conducted at the University of Iowa.